Allogene Therapeutics, Inc. (ALLO)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allogene Therapeutics, Inc. (ALLO) trades at $2.14 with AI Score 25/100 (Grade F). Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing allogeneic T cell therapies for cancer treatment. Market cap: $521.88M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026ALLO stock analysis for 2026: Analysts have set a consensus price target of $6.43 for Allogene Therapeutics, Inc., suggesting 200.5% upside from the current price of $2.14. The AI MoonshotScore is 25/100, indicating a bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ALLO: 1/1 perspectives are bearish.
How is this calculated? →Allogene Therapeutics, Inc. (ALLO) Healthcare & Pipeline Overview
Allogene Therapeutics is a clinical-stage biotechnology firm specializing in the development of allogeneic CAR T-cell therapies for cancer. Their pipeline includes candidates targeting lymphomas, multiple myeloma, and acute myeloid leukemia, positioning them in the competitive immuno-oncology market.
What Is the Investment Thesis for ALLO?
Allogene Therapeutics presents a notable research candidate within the immuno-oncology space, driven by its focus on allogeneic CAR T-cell therapies. The company's pipeline, featuring UCART19 and ALLO-501, targets significant unmet needs in hematologic malignancies. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The potential for off-the-shelf CAR T-cell therapies offers a significant advantage over autologous approaches, reducing manufacturing complexity and treatment timelines. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and competition from established players in the cell therapy market. Investors should closely monitor clinical trial data and regulatory milestones to assess the company's progress.
Based on FMP financials and quantitative analysis
ALLO Key Highlights
- Market capitalization of $521.88M reflects investor sentiment regarding Allogene's pipeline and potential.
- Beta of 0.50 indicates lower volatility compared to the broader market, suggesting a more stable investment profile.
- Focus on allogeneic CAR T-cell therapies addresses the limitations of autologous approaches, offering scalability and cost-effectiveness.
- Strategic collaborations with Pfizer, Servier, and Cellectis provide access to resources and expertise, enhancing development capabilities.
- Multiple clinical trials underway across various hematologic malignancies demonstrate a diversified pipeline and potential for multiple product approvals.
Who Are ALLO's Competitors?
ALLO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NVS Novartis AG | $155.20 | -2.94% | $296.14B | 57 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| CLLS Cellectis S.A. | $3.27 | -0.91% | $328.36M | 62 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALLO's Key Strengths?
- Proprietary allogeneic CAR T-cell technology platform.
- Strong pipeline of product candidates targeting various hematologic malignancies.
- Strategic collaborations with leading research institutions and pharmaceutical companies.
- Experienced management team with expertise in cell therapy development.
What Are ALLO's Weaknesses?
- Clinical stage company with no approved products and no revenue.
- High research and development expenses.
- Dependence on clinical trial success and regulatory approvals.
- Potential for manufacturing challenges and scalability issues.
What Could Drive ALLO Stock Higher?
- Data readouts from ongoing Phase 1/2 clinical trials of ALLO-501A in R/R large B-cell lymphoma.
- Initiation of Phase 2 clinical trials for ALLO-715 in R/R multiple myeloma.
- Advancement of preclinical programs targeting solid tumors with allogeneic CAR T-cell therapies.
- Expansion of strategic collaborations with pharmaceutical companies and research institutions.
What Are the Key Risks for ALLO?
- Financial-distress signal — its Altman Z-Score of -5.36 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-56.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays could negatively impact the company's pipeline and valuation.
- Regulatory setbacks or changes in reimbursement policies could hinder commercialization efforts.
- Competition from established players in the cell therapy market could limit market share.
- Adverse events or safety concerns associated with CAR T-cell therapy could impact patient adoption.
- Manufacturing challenges or scalability issues could delay product launches and increase costs.
What Are the Growth Opportunities for ALLO?
- Expansion into Solid Tumors: Allogene has the opportunity to extend its allogeneic CAR T-cell technology into solid tumors, addressing a significantly larger patient population. The solid tumor market represents a substantial growth opportunity, with a potential market size exceeding $50 billion. Success in this area would require overcoming challenges related to tumor microenvironment and antigen specificity, but could significantly expand Allogene's market reach. Timeline: Ongoing preclinical research and early-stage clinical trials.
- Strategic Partnerships and Acquisitions: Allogene can pursue strategic partnerships and acquisitions to enhance its technology platform, expand its pipeline, and accelerate commercialization. Collaborations with companies possessing complementary technologies or access to new markets could create synergies and drive growth. The market for cell therapy companies is active, with numerous opportunities for strategic transactions. Timeline: Ongoing, with potential for deals in the next 1-3 years.
- Advancements in Manufacturing Processes: Improving the efficiency and scalability of its allogeneic CAR T-cell manufacturing processes is crucial for reducing costs and increasing accessibility. Innovations in manufacturing technologies, such as closed systems and automation, can drive down production costs and improve product consistency. This will be critical for competing with autologous therapies on price. Timeline: Ongoing process optimization and technology development.
- Expansion of Pipeline with Novel Targets: Allogene can expand its pipeline by identifying and validating new targets for allogeneic CAR T-cell therapy. Targeting novel antigens expressed on cancer cells can open up new therapeutic avenues and address unmet needs in various malignancies. This requires investment in research and development, but can lead to the creation of innovative products with significant market potential. Timeline: Ongoing research and development efforts.
- Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, represents a significant growth opportunity for Allogene. These markets have a growing demand for innovative cancer therapies and offer favorable regulatory environments for cell therapy products. Establishing partnerships with local distributors and healthcare providers can facilitate market entry and accelerate adoption. Timeline: Potential expansion within the next 3-5 years.
What Opportunities Does ALLO Have?
- Expansion into solid tumors with allogeneic CAR T-cell therapy.
- Strategic partnerships and acquisitions to enhance technology platform and pipeline.
- Advancements in manufacturing processes to reduce costs and increase accessibility.
- Geographic expansion into new markets.
What Threats Does ALLO Face?
- Competition from established players in the cell therapy market.
- Clinical trial failures and regulatory setbacks.
- Adverse events and safety concerns associated with CAR T-cell therapy.
- Changes in reimbursement policies and healthcare regulations.
What Are ALLO's Competitive Advantages?
- Proprietary allogeneic CAR T-cell technology platform.
- Extensive intellectual property portfolio covering its product candidates and manufacturing processes.
- Strategic collaborations with leading research institutions and pharmaceutical companies.
- Expertise in cell therapy manufacturing and development.
What Does ALLO Do?
Allogene Therapeutics, Inc. is an immuno-oncology company dedicated to developing and commercializing genetically engineered allogeneic T cell therapies for cancer treatment. Founded in 2017 and headquartered in South San Francisco, California, Allogene aims to revolutionize cancer treatment through its innovative approach to cell therapy. The company's lead product candidate, UCART19, is designed to treat pediatric and adult patients with relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL). Allogene is also developing ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma, and ALLO-501A, in Phase I/II trials for R/R large B-cell lymphoma or transformed follicular lymphoma. Their pipeline extends to include ALLO-715 for R/R multiple myeloma, ALLO-605 for multiple myeloma, ALLO-647, an anti-CD52 monoclonal antibody, CD70 for renal cell cancer, ALLO-819 for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene has established strategic collaborations with Pfizer Inc., Servier, Cellectis S.A., Notch Therapeutics Inc., and SpringWorks Therapeutics, Inc., as well as The University of Texas MD Anderson Cancer Center, to advance its research and development efforts.
What Products and Services Does ALLO Offer?
- Develops genetically engineered allogeneic T cell therapies for cancer treatment.
- Focuses on off-the-shelf CAR T-cell therapies.
- Manufactures and commercializes UCART19 for R/R CD19 positive B-cell ALL.
- Develops ALLO-501 for R/R non-Hodgkin lymphoma.
- Develops ALLO-501A for R/R large B-cell lymphoma or transformed follicular lymphoma.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Collaborates with leading research institutions and pharmaceutical companies.
How Does ALLO Make Money?
- Develops and patents allogeneic CAR T-cell therapy technologies.
- Out-licenses or co-develops therapies with pharmaceutical partners.
- Generates revenue through milestone payments, royalties, and product sales upon regulatory approval.
- Focuses on hematologic malignancies and solid tumors.
What Industry Does ALLO Operate In?
Allogene Therapeutics operates within the rapidly evolving immuno-oncology market, specifically focusing on cell therapies. The CAR T-cell therapy market is projected to experience substantial growth, driven by increasing prevalence of hematologic malignancies and advancements in genetic engineering. Competition is intense, with established players like Novartis and Gilead Sciences, as well as emerging biotech companies, vying for market share. Allogene's allogeneic approach offers a potential advantage over autologous therapies, addressing scalability and cost challenges. The company's success hinges on demonstrating clinical efficacy and safety, navigating regulatory pathways, and securing reimbursement approvals.
Who Are ALLO's Key Customers?
- Patients with relapsed or refractory hematologic malignancies.
- Hospitals and oncology clinics.
- Pharmaceutical companies through partnerships and collaborations.
- Research institutions for preclinical and clinical research.
Company Profile
Allogene Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO David D. Chang. ALLO has traded publicly since 2018.
F-Score 1/9Financial Health
Allogene Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.36 places it in the distress zone, a signal of elevated financial risk.
ROE -56%Key Financial Metrics
Return on equity for Allogene Therapeutics, Inc. stands at -56.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -43.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -20.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -33.3%, the inverse of the P/E and a quick read on earnings relative to price.
ALLO Valuation & Market Position
With a $521.88M market cap, Allogene Therapeutics, Inc. sits in the small-cap segment of the market. Relative to its peer group, ALLO's quantitative score of 25/100 is below the peer average of 74/100.
FY2026 estForward Outlook
Wall Street analysts project Allogene Therapeutics, Inc. revenue of about $5K for fiscal 2026, with EPS near $-0.70. The estimate reflects 7 contributing analysts.
Net buyingInsider Activity
Over the past six months, Allogene Therapeutics, Inc. insiders filed 26 SEC Form 4 transactions — 12 sales and 14 purchases. On net that is roughly 5.7M shares acquired (about $8.2M) — insiders putting money in tends to read as conviction.
ALLO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's pipeline and future growth potential.
- Community sentiment has shifted positively as recent clinical trial results have sparked renewed interest in their CAR T-cell therapies.
- Increased collaborations with research institutions have enhanced credibility and visibility in the biotech space.
- Positive media coverage highlighting advancements in their technology has boosted investor enthusiasm.
Bear Case
- Concerns over regulatory hurdles for new therapies could dampen investor sentiment in the near term.
- Recent bearish community discussions reflect skepticism about the commercialization timeline for their lead products.
- Market volatility in the biotech sector has raised caution among investors, leading to a more cautious outlook.
- Insider selling activity noted in the past month has raised questions about the long-term confidence of some stakeholders.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ALLO Latest News
-
Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial
Exec Edge · Jun 30, 2026
-
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
Yahoo! Finance: ALLO News · Jun 17, 2026
-
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
zacks.com · Jun 12, 2026
-
FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases
Exec Edge · Jun 9, 2026
ALLO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALLO.
Price Targets
Consensus target: $6.43
ALLO MoonshotScore
What does this score mean?
The MoonshotScore rates ALLO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
FDA Clears Imviva’s Dual-Target CAR-T for Autoimmune Diseases
Leadership: David D. Chang
Chief Executive Officer
David D. Chang serves as the Chief Executive Officer of Allogene Therapeutics, bringing extensive experience in the biotechnology and pharmaceutical industries. Prior to Allogene, he held leadership positions at Kite Pharma, where he played a key role in the development and commercialization of CAR T-cell therapies. His career also includes roles at Amgen and other leading healthcare companies. He has a strong background in clinical development, regulatory affairs, and commercial strategy.
Track Record: Under David Chang's leadership, Allogene Therapeutics has advanced its pipeline of allogeneic CAR T-cell therapies through multiple clinical trials. He has overseen strategic collaborations with leading research institutions and pharmaceutical companies, and has successfully raised capital to support the company's research and development efforts. His leadership has been instrumental in establishing Allogene as a key player in the immuno-oncology space.
Common Questions About ALLO (Healthcare)
What does Allogene Therapeutics, Inc. do?
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing allogeneic CAR T-cell therapies for the treatment of cancer. Unlike autologous CAR T-cell therapies, which are derived from a patient's own cells, Allogene's therapies are developed from healthy donors, creating off-the-shelf products that can be readily available for patients. This approach aims to overcome the limitations of autologous therapies, such as manufacturing complexity and treatment delays, offering a more scalable and accessible solution for cancer treatment.
What do analysts say about ALLO stock?
Analyst consensus on Allogene Therapeutics (ALLO) reflects a cautiously optimistic outlook, primarily driven by the potential of its allogeneic CAR T-cell therapy platform. Key valuation metrics often focus on the long-term revenue potential of its pipeline candidates, particularly in hematologic malignancies. Growth considerations revolve around successful clinical trial outcomes, regulatory approvals, and market penetration. Analysts closely monitor clinical data readouts and regulatory milestones to assess the company's progress and adjust their price targets accordingly. However, the inherent risks associated with clinical-stage biotechnology companies are also factored into their assessments.
What are the main risks for ALLO?
The main risks for Allogene Therapeutics (ALLO) are inherent to its stage and industry. As a clinical-stage biotechnology company, Allogene faces significant clinical trial risk; failure or delays in trials for its CAR T-cell therapies would severely impact its prospects. Regulatory hurdles also pose a substantial risk, as the path to approval for novel cell therapies is complex and uncertain. Competition within the immuno-oncology space is intense, with established players and emerging companies vying for market share. Manufacturing scalability and cost-effectiveness are also critical risks, as Allogene must demonstrate its ability to produce its therapies at a commercially viable scale. Furthermore, safety concerns associated with CAR T-cell therapies, such as cytokine release syndrome, could impact patient adoption and regulatory approval.
What are the key factors to evaluate for ALLO?
Allogene Therapeutics, Inc. (ALLO) holds an AI score of 25/100 (low). Analysts target $6.43 (+200%). Not financial advice.
How frequently does ALLO data refresh on this page?
ALLO prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ALLO's recent stock price performance?
Allogene Therapeutics, Inc. (ALLO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary allogeneic CAR T-cell technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALLO overvalued or undervalued right now?
Valuing Allogene Therapeutics, Inc. (ALLO) requires multiple metrics. Analysts target $6.43 (+200%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ALLO?
Before investing in Allogene Therapeutics, Inc. (ALLO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Clinical trial outcomes are inherently uncertain and may impact future results.